Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic presents a selection of updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials. The Coronavirus pandemic is an accelerator for digitalization in many industries, including clinical trials. This book considers best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of "virtualized" protocols, and moving from data to decisions. This book will be helpful to pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design.
- Considers multiple digital and virtual strategies
- Explores best practices, including the use of reduced patient involvement
- Brings together expert, trusted information to increase the efficiency and effectiveness of clinical trials
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
"Much has been written on the correlation between crises and innovation. Our hope is that the COVID-19 crisis catalyzes enduring changes to clinical trial methodologies, ones that serve patients today and for years to come.
Peter Schüler has created a timely textbook for all involved in the critical processes of clinical trial conduct. He has brilliantly set the stage for a possible dramatic evolution of clinical trial strategy, methodology, conduct, and interpretation; this evolution will be essential to address patients' needs not just now during the pandemic but will endure and be applied broadly to many other diseases and therapies." --Barbara Lopez Kunz, President and Global Chief Executive, DIA (Drug Information Association)
Peter Schüler has created a timely textbook for all involved in the critical processes of clinical trial conduct. He has brilliantly set the stage for a possible dramatic evolution of clinical trial strategy, methodology, conduct, and interpretation; this evolution will be essential to address patients' needs not just now during the pandemic but will endure and be applied broadly to many other diseases and therapies." --Barbara Lopez Kunz, President and Global Chief Executive, DIA (Drug Information Association)